Current progress in the development of a prophylactic vaccine for HIV-1

Drug Design, Development and Therapy

Volumn , Issue 5, 2011, Pages 9-26

  Gamble, Lena J ^a   Matthews, Qiana L ^a,b  

^a Gene Therapy Center   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

AIDS; HIV; Prophylactic vaccine; Sterilizing immunity; Viral vectors

Indexed keywords

AIDSVAX B E; ALVAC HIV; CAPSID PROTEIN; CHIMERIC PROTEIN; DNA VACCINE; GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LUCIFERASE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; NEF PROTEIN; PLACEBO; PLASMID DNA; POL PROTEIN; POLYHISTIDINE TAG; PROTEIN VP1; RECOMBINANT VACCINE; REV PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS CAPSID ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR; VPR PROTEIN; VPU PROTEIN;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CELLULAR IMMUNITY; DNA IMMUNIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; HYDRODYNAMICS BASED TRANSFECTION; IMMUNE EVASION; IMMUNE RESPONSE; INFECTION PREVENTION; MICROBIAL DIVERSITY; MUCOSAL IMMUNITY; NONHUMAN; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS IMMUNITY; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT;

EID: 79952923201     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S6959     Document Type: Review

References (260)

1. UNAIDS. 2008 Report on the Global AIDS Epidemic. 2010. Available from: http://www.unaids.org/en/KnowledgeCentre/HIVData/ GlobalReport/2008/2008_Global_report.asp. Accessed 2010 Oct 3.
2. Duggan JM, Locher A, Fink B, Okonta C, Chakraborty J. Adherence to antiretroviral therapy: a survey of factors associated with medication usage. AIDS Care. 2009;21(9):1141-1147.
3. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis. 2000;31(6): 1482-1487.
4. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14(3):F25-F32.
5. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36(4): 482-490.
6. Noe A, Plum J, Verhofstede C. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance.J Antimicrob Chemother. 2005;55(4):410-412.
7. Shacklett BL. Mucosal immunity to HIV: a review of recent literature. Curr Opin HIV AIDS. 2008;3(5):541-547.
8. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 2004;5(3):233-236.
9. McMichael AJ. HIV vaccines. Annu Rev Immunol. 2006;24:227-255.
10. Emini EA, Koff WC. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope. Science. 2004;304(5679):1913-1914.
11. Thorner AR, Barouch DH. HIV-1 vaccine development: progress and prospects. Curr Infect Dis Rep. 2007;9(1):71-75.
12. Robinson HL, Amara RR. T cell vaccines for microbial infections. Nat Med. 2005;11 Suppl 4:S25-S32.
13. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med. 2008; 205(1):7-12.
14. Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet. 1995;345(8961):1342-1344.
15. Stahl-Hennig C, Dittmer U, Nisslein T, et al. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J Gen Virol. 1996;77(Pt 12):2969-2981.
16. Learmont J, Tindall B, Evans L, et al. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet. 1992;340(8824):863-867.
17. Berkhout B, Verhoef K, van Wamel JL, Back NK. Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains. J Virol. 1999;73(2):1138-1145.
18. Learmont J, Cook L, Dunckley H, Sullivan JS. Update on long-term symptomless HIV type 1 infection in recipients of blood products from a single donor. AIDS Res Hum Retroviruses. 1995;11(1):1.
19. Duerr A, Wasserheit JN, Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis. 2006;43(4):500-511.
20. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191(5): 654-665.
21. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis. 2005;191(5):666-677.
22. Graham BS, Mascola JR. Lessons from failure - preparing for future HIV-1 vaccine efficacy trials. J Infect Dis. 2005;191(5):647-649.
23. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;194(12):1661-1671.
24. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006;20(16):W13-W23.
25. Plantier JC, Leoz M, Dickerson JE, et al. A new human immunodeficiency virus derived from gorillas. Nat Med. 2009;15(8):871-872.
26. Renjifo B, Gilbert P, Chaplin B, et al. Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS. 2004;18(12):1629-1636.
27. Bhoopat L, Rithaporn TS, Khunamornpong S, Bhoopat T, Taylor CR, Thorner PS. Cell reservoirs in lymph nodes infected with HIV-1 subtype E differ from subtype B: identification by combined in situ polymerase chain reaction and immunohistochemistry. Mod Pathol. 2006;19(2):255-263.
28. Vasan A, Renjifo B, Hertzmark E, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis. 2006;42(6):843-852.
29. Kaleebu P, Nankya IL, Yirrell DL, et al. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr. 2007;45(1):28-33.
30. Cohen J. HIV. Escape artist par excellence. Science. 2003;299(5612): 1505-1508.
31. Moore JP, Parren PW, Burton DR. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol. 2001;75(13):5721-5729.
32. McBurney SP, Ross TM. Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev Vaccines. 2008;7(9):1405-1417.
33. Seaman MS, Leblanc DF, Grandpre LE, et al. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology. 2007;367(1):175-186.
34. Kibuuka H, Kimutai R, Maboko L, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis. 2010;201(4):600-607.
35. Santra S, Liao HX, Zhang R, et al. Mosaic vaccines elicit CD8(+) T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med. 2010;16(3):324-328.
36. Corey L, McElrath MJ. HIV vaccines: mosaic approach to virus diversity. Nat Med. 2010;16(3):268-270.
37. Barouch DH, O'Brien KL, Simmons NL, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med. 2010;16(3):319-323.
38. Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol. 2001;75(17):8340-8347.
39. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000;6(2):200-206.
40. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6(2):207-210.
41. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull. 2001;58:19-42.
42. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 1998;393(6686): 705-711.
43. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998;393(6686):648-659.
44. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422(6929):307-312.
45. Fenouillet E, Barbouche R, Jones IM. Cell entry by enveloped viruses: redox considerations for HIV and SARS-coronavirus. Antioxid Redox Signal. 2007;9(8):1009-1034.
46. DeVico A, Fouts T, Lewis GK, et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci U S A. 2007;104(44):17477-17482.
47. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326(5950):285-289.
48. Burton DR, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994;266(5187):1024-1027.
49. Muster T, Steindl F, Purtscher M, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993;67(11):6642-6647.
50. Stiegler G, Kunert R, Purtscher M, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2001;17(18):1757-1765.
51. Trkola A, Pomales AB, Yuan H, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol. 1995;69(11):6609-6617.
52. Lagenaur LA, Villarroel VA, Bundoc V, Dey B, Berger EA. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology. 2010;7:11.
53. Corti D, Langedijk JP, Hinz A, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One. 2010;5(1): e8805.
54. Easterbrook PJ, Schrager LK. Long-term nonprogression in HIV infection: methodological issues and scientific priorities. Report of an International European Community-National Institutes of Health Workshop, The Royal Society, London, England, 1995 Nov 27-29. Scientific Coordinating Committee. AIDS Res Hum Retroviruses. 1998; 14(14):1211-1228.
55. Paroli M, Propato A, Accapezzato D, Francavilla V, Schiaffella E, Barnaba V. The immunology of HIV-infected long-term nonprogressors-a current view. Immunol Lett. 2001;79(1-2):127-129.
56. Johnson BK, Stone GA, et al. Long-term observations of human immunodeficiency virus-infected chimpanzees. AIDS Res Hum Retroviruses. 1993;9(4):375-378.
57. Gardner MB. Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents. Antiviral Res. 1991;15(4):267-286.
58. Podell M, March PA, Buck WR, Mathes LE. The feline model of neuroAIDS: understanding the progression towards AIDS dementia. J Psychopharmacol. 2000;14(3):205-213.
59. Yamamoto JK, Sanou MP, Abbott JR, Coleman JK. Feline immunodeficiency virus model for designing HIV/AIDS vaccines. Curr HIV Res. 2010;8(1):14-25.
60. Mosier DE, Gulizia RJ, Baird SM, Wilson DB, Spector DH, Spector SA. Human immunodeficiency virus infection of human-PBL-SCID mice. Science. 1991;251(4995):791-794.
61. McCune JM, Namikawa R, Shih CC, Rabin L, Kaneshima H. Suppression of HIV infection in AZT-treated SCID-hu mice. Science. 1990; 247(4942):564-566.
62. Baenziger S, Tussiwand R, Schlaepfer E, et al. Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice. Proc Natl Acad Sci U S A. 2006;103(43): 15951-15956.
63. Gardner MB, Luciw PA. Animal models of AIDS. FASEB J. 1989;3(14): 2593-2606.
64. Li J, Lord CI, Haseltine W, Letvin NL, Sodroski J. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr. 1992; 5(7):639-646.
65. Reimann KA, Li JT, Veazey R, et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol. 1996;70(10):6922-6928.
66. Nishimura Y, Igarashi T, Donau OK, et al. Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc Natl Acad Sci U S A. 2004;101(33):12324-12329.
67. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a doubleblind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881-1893.
68. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002;415(6869):331-335.
69. Kestler HW III, Ringler DJ, Mori K, et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell. 1991;65(4):651-662.
70. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992;258(5090): 1938-1941.
71. Rud EW, Cranage M, Yon J, et al. Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J Gen Virol. 1994;75(Pt 3):529-543.
72. Cranage MP, Whatmore AM, Sharpe SA, et al. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology. 1997;229(1):143-154.
73. Marthas ML, Sutjipto S, Higgins J, et al. Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J Virol. 1990;64(8):3694-3700.
74. Shacklett BL, Shaw KE, Adamson LA, et al. Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251. J Virol. 2002;76(22):11365-11378.
75. Protection of macaques against simian immunodeficiency virus infection with inactivated vaccines: comparison of adjuvants, doses and challenge viruses. The European Concerted Action on 'Macaque Models for AIDS Research'. Vaccine. 1995;13(3):295-300.
76. Putkonen P, Nilsson C, Hild K, et al. Whole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cells. J Med Primatol. 1993;22(2-3):100-103.
77. Stahl-Hennig C, Voss G, Dittmer U, et al. Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus. AIDS. 1993;7(6):787-795.
78. Kusuhara H, Hohdatsu T, Okumura M, et al. Dual-subtype vaccine (Fel- O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats. Vet Microbiol. 2005;108(3-4):155-165.
79. Pu R, Coleman J, Omori M, et al. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. AIDS. 2001;15(10):1225-1237.
80. Hohdatsu T, Okada S, Motokawa K, Aizawa C, Yamamoto JK, Koyama H. Effect of dual-subtype vaccine against feline immunodeficiency virus infection. Vet Microbiol. 1997;58(2-4):155-165.
81. Pu R, Coleman J, Coisman J, et al. Dual-subtype FIV vaccine (Fel- O-Vax FIV) protection against a heterologous subtype B FIV isolate. J Feline Med Surg. 2005;7(1):65-70.
82. Birx DL, Loomis-Price LD, Aronson N, et al. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 hase II Vaccine Investigators. J Infect Dis. 2000;181(3):881-889.
83. Eron JJ Jr, Ashby MA, Giordano MF, et al. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet. 1996;348(9041):1547-1551.
84. Pontesilli O, Guerra EC, Ammassari A, et al. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team. AIDS. 1998;12(5):473-480.
85. Ratto-Kim S, Sitz KV, Garner RP, et al. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response. J Infect Dis. 1999;179(2):337-344.
86. Redfield RR, Birx DL, Ketter N, et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med. 1991;324(24):1677-1684.
87. Schooley RT, Spino C, Kuritzkes D, et al. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 a nd 214. J Infect Dis. 2000;182(5):1357-1364.
88. Valentine FT, Kundu S, Haslett PA, et al. A randomized, placebocontrolled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with. or = 400/ mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). J Infect Dis. 1996;173(6):1336-1346.
89. Wahren B, Bratt G, Persson C, et al. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr. 1994;7(3):220-229.
90. Wright PF, Lambert JS, Gorse GJ, et al. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women. J Infect Dis. 1999;180(4):1080-1088.
91. Weber J, Cheinsong-Popov R, Callow D, et al. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine. 1995;13(9):831-834.
92. Veenstra J, Williams IG, Colebunders R, et al. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. J Infect Dis. 1996; 174(4):862-866.
93. Kelleher AD, Roggensack M, Jaramillo AB, et al. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators. AIDS. 1998;12(2):175-182.
94. Benson EM, Clarkson J, Law M, et al. Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. AIDS Res Hum Retroviruses. 1999;15(2):105-113.
95. Okuda K, Bukawa H, Hamajima K, et al. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res Hum Retroviruses. 1995; 11(8):933-943.
96. Neumann J, Stitz J, Konig R, et al. Retroviral vectors for vaccine development: induction of HIV-1-specific humoral and cellular immune responses in rhesus macaques using a novel MLV(HIV-1) pseudotype vector. J Biotechnol. 2006;124(3):615-625.
97. Buffa V, Negri DR, Leone P, et al. A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice. J Gen Virol. 2006;87(Pt 6):1625-1634.
98. Faul EJ, Aye PP, Papaneri AB, et al. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine. 2009;28(2):299-308.
99. McKenna PM, Koser ML, Carlson KR, et al. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J Infect Dis. 2007;195(7):980-988.
100. Quinnan GV Jr, Yu XF, Lewis MG, et al. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J Virol. 2005;79(6):3358-3369.
101. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209-2220.
102. Johnson PR, Schnepp BC, Zhang J, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med. 2009;15(8):901-906.
103. Chenciner N, Randrianarison-Jewtoukoff V, Delpeyroux F, et al. Enhancement of humoral immunity to SIVenv following simultaneous inoculation of mice by three recombinant adenoviruses encoding SIVenv/poliovirus chimeras, Tat and Rev. AIDS Res Hum Retroviruses. 1997;13(9):801-806.
104. Santra S, Seaman MS, Xu L, et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol. 2005;79(10):6516-6522.
105. Natuk RJ, Davis AR, Chanda PK, et al. Adenovirus vectored vaccines. Dev Biol Stand. 1994;82:71-77.
106. Bruce CB, Akrigg A, Sharpe SA, Hanke T, Wilkinson GW, Cranage MP. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice. J Gen Virol. 1999; 80(Pt 10): 2621-2628.
107. Zhan X, Martin LN, Slobod KS, et al. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine. 2005;23(46-47): 5306-5320.
108. Laube LS, Burrascano M, Dejesus CE, et al. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins. Hum Gene Ther. 1994;5(7):853-862.
109. Buffa V, Negri DR, Leone P, et al. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo. Viral Immunol. 2006;19(4):690-701.
110. Halsey RJ, Tanzer FL, Meyers A, et al. Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles. Virus Res. 2008;133(2):259-268.
111. Pillay S, Meyers A, Williamson AL, Rybicki EP. Optimization of chimeric HIV-1 virus-like particle production in a baculovirus-insect cell expression system. Biotechnol Prog. 2009;25(4):1153-1160.
112. Deml L, Kratochwil G, Osterrieder N, Knuchel R, Wolf H, Wagner R. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55 gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology. 1997;235(1):10-25.
113. Deml L, Schirmbeck R, Reimann J, Wolf H, Wagner R. Recombinant human immunodeficiency Pr55 gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology. 1997;235(1):26-39.
114. Kang CY, Luo L, Wainberg MA, Li Y. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Biol Chem. 1999; 380(3):353-364.
115. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol. 1997;15:617-648.
116. Garzon MR, Berraondo P, Crettaz J, et al. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine- plasmid complex. Vaccine. 2005;23(11):1384-1392.
117. Liu MA. DNA vaccines: a review. J Intern Med. 2003;253(4): 402-410.
118. Raska M, Belakova J, Wudattu NK, et al. Comparison of protective effect of protein and DNA vaccines hsp90 in murine model of systemic candidiasis. Folia Microbiol (Praha). 2005;50(1):77-82.
119. Giri M, Ugen KE, Weiner DB. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev. 2004;17(2):370-389.
120. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465-1468.
121. Calarota SA, Weiner DB. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev. 2004;199:84-99.
122. Billaut-Mulot O, Idziorek T, Loyens M, Capron A, Bahr GM. Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/ viral protein boost. Vaccine. 2001;19(20-22):2803-2811.
123. Dale CJ, de Rose R, Wilson KM, et al. Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12. Vaccine. 2004;23(2): 188-197.
124. Barouch DH, Santra S, Steenbeke TD, et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol. 1998;161(4):1875-1882.
125. Hashida M, Nishikawa M, Yamashita F, Takakura Y. Cell-specific delivery of genes with glycosylated carriers. Adv Drug Deliv Rev. 2001;52(3):187-196.
126. Zhang Y, Schlachetzki F, Li JY, Boado RJ, Pardridge WM. Organspecific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol Vis. 2003;9:465-472.
127. Zou SM, Erbacher P, Remy JS, Behr JP. Systemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouse. J Gene Med. 2000;2(2):128-134.
128. Zuber G, Zammut-Italiano L, Dauty E, Behr JP. Targeted gene delivery to cancer cells: directed assembly of nanometric DNA particles coated with folic acid. Angew Chem Int Ed Engl. 2003;42(23): 2666-2669.
129. Harari A, Bart PA, Stohr W, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 2008;205(1):63-77.
130. Jaoko W, Karita E, Kayitenkore K, et al. Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One. 2010;5(9):e12873.
131. Combe E, Pirman T, Stekar J, Houlier ML, Mirand PP. Differential effect of lentil feeding on proteosynthesis rates in the large intestine, liver and muscle of rats. J Nutr Biochem. 2004;15(1):12-17.
132. Raska M, Moldoveanu Z, Novak J, et al. Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses. Vaccine. 2008;26(12):1541-1551.
133. Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med. 2003;9(7):861-866.
134. Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in AIDS. Nat Med. 1998;4(6):679-684.
135. Heller L, Jaroszeski MJ, Coppola D, Pottinger C, Gilbert R, Heller R. Electrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivo. Gene Ther. 2000;7(10):826-829.
136. Vorup-Jensen T, Jensen UB, Liu H, et al. Tail-vein injection of mannan-binding lectin DNA leads to high expression levels of multimeric protein in liver. Mol Ther. 2001;3(6):867-874.
137. Budker VG, Subbotin VM, Budker T, Sebestyen MG, Zhang G, Wolff JA. Mechanism of plasmid delivery by hydrodynamic tail vein injection. II. Morphological studies. J Gene Med. 2006;8(7):874-888.
138. Sebestyen MG, Budker VG, Budker T, et al. Mechanism of plasmid delivery by hydrodynamic tail vein injection. I. Hepatocyte uptake of various molecules. J Gene Med. 2006;8(7):852-873.
139. Budker V, Zhang G, Danko I, Williams P, Wolff J. The efficient expression of intravascularly delivered DNA in rat muscle. Gene Ther. 1998;5(2):272-276.
140. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999;6(7):1258-1266.
141. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther. 1999;10(10):1735-1737.
142. Suda T, Liu D. Hydrodynamic gene delivery: its principles and applications. Mol Ther. 2007; 15(12):2063-2069.
143. Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev. 1995;75(3): 591-609.
144. Maier MA, Yannopoulos CG, Mohamed N, et al. Synthesis of antisense oligonucleotides conjugated to a multivalent carbohydrate cluster for cellular targeting. Bioconjug Chem. 2003;14(1):18-29.
145. Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell. 2008;132(3): 397-409.
146. Kalyuzhniy O, di Paolo NC, Silvestry M, et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A. 2008;105(14):5483-5488.
147. Li S, Locke E, Bruder J, et al. Viral vectors for malaria vaccine development. Vaccine. 2007;25(14):2567-2574.
148. Smith AD, Geisler SC, Chen AA, et al. Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1. J Virol. 1998;72(1):651-659.
149. Arnold GF, Velasco PK, Holmes AK, et al. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol. 2009;83(10):5087-5100.
150. Patterson S, Papagatsias T, Benlahrech A. Use of adenovirus in vaccines for HIV. Handb Exp Pharmacol. 2009;(188):275-293.
151. Bangari DS, Mittal SK. Development of nonhuman adenoviruses as vaccine vectors. Vaccine. 2006;24(7):849-862.
152. Crotty S, Andino R. Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine. Adv Drug Deliv Rev. 2004;56(6):835-852.
153. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001;292(5514):69-74.
154. Gherardi MM, Esteban M. Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol. 2005;86(Pt 11):2925-2936.
155. Langley WA, Bradley KC, Li ZN, Smith ME, Schnell MJ, Steinhauer DA. Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways. J Virol. 2010;84(16): 8300-8307.
156. Slobod KS, Lockey TD, Howlett N, et al. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Microbiol Infect Dis. 2004;23(2):106-110.
157. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998;72(12):9706-9713.
158. Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochim Biophys Acta. 2002;1575(1-3):1-14.
159. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001;7(1):33-40.
160. Tangy F, Naim HY. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol. 2005;18(2): 317-326.
161. Esolen LM, Ward BJ, Moench TR, Griffin DE. Infection of monocytes during measles. J Infect Dis. 1993;168(1):47-52.
162. Hilleman MR. Vaccinology, immunology, and comparative pathogenesis of measles in the quest for a preventative against AIDS. AIDS Res Hum Retroviruses. 1994;10(1):3-12.
163. Mandl S, Hix L, Andino R. Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors. J Virol. 2001;75(2):622-627.
164. Thacker E, Timares L, Matthews QL. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines. 2009;8(6):761-777.
165. Sumida SM, Truitt DM, Lemckert AA, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol. 2005;174(11):7179-7185.
166. Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, Curiel DT. Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol. 2002;76(24):12775-12782.
167. Roberts DM, Nanda A, Havenga MJ, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature. 2006;441(7090):239-243.
168. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999;6(9):1574-1583.
169. Kass-Eisler A, Falck-Pedersen E, Elfenbein DH, Alvira M, Buttrick PM, Leinwand LA. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther. 1994;1(6):395-402.
170. Kass-Eisler A, Leinwand L, Gall J, Bloom B, Falck-Pedersen E. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther. 1996;3(2):154-162.
171. Youil R, Toner TJ, Su Q, et al. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther. 2002;13(2):311-320.
172. Mastrangeli A, Harvey BG, Yao J, et al. 'Sero-switch' adenovirusmediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther. 1996;7(1):79-87.
173. Moffatt S, Hays J, HogenEsch H, Mittal SK. Circumvention of vectorspecific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology. 2000;272(1):159-167.
174. Lemckert AA, Grimbergen J, Smits S, et al. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol. 2006;87(Pt 10):2891-2899.
175. Shayakhmetov DM, Lieber A. Dependence of adenovirus infectivity on length of the fiber shaft domain. J Virol. 2000;74(22):10274-10286.
176. Kidd AH, Chroboczek J, Cusack S, Ruigrok RW. Adenovirus type 40 virions contain two distinct fibers. Virology. 1993;192(1):73-84.
177. Yeh HY, Pieniazek N, Pieniazek D, Gelderblom H, Luftig RB. Human adenovirus type 41 contains two fibers. Virus Res. 1994;33(2): 179-198.
178. Pichla-Gollon SL, Drinker M, Zhou X, et al. Structure-based identification of a major neutralizing site in an adenovirus hexon. J Virol. 2007;81(4):1680-1689.
179. Roy S, Gao G, Lu Y, et al. Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum Gene Ther. 2004;15(5):519-530.
180. Farina SF, Gao GP, Xiang ZQ, et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol. 2001;75(23): 11603-11613.
181. Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006;346(2): 394-401.
182. Umana P, Gerdes CA, Stone D, et al. Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol. 2001;19(6):582-585.
183. Lowenstein PR, Thomas CE, Umana P, et al. High-capacity, helperdependent, 'gutless' adenoviral vectors for gene transfer into brain. Methods Enzymol. 2002;346:292-311.
184. Xiong W, Goverdhana S, Sciascia SA, et al. Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol. 2006;80(1):27-37.
185. Xiong W, Candolfi M, Kroeger KM, et al. Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. Mol Ther. 2008;16(2):343-351.
186. Weaver EA, Nehete PN, Buchl SS, et al. Comparison of replicationcompetent, first generation, and helper-dependent adenoviral vaccines. PLoS One. 2009;4(3):e5059.
187. Weaver EA, Nehete PN, Nehete BP, et al. Protection against mucosal SHIV challenge by peptide and helper-dependent adenovirus vaccines. Viruses. 2009;1(3):920-938.
188. Weaver EA, Barry MA. Effects of shielding adenoviral vectors with polyethylene glycol (PEG) on vector-specific and vaccine-mediated immune responses. Hum Gene Ther. 2008;19(12):1369-1382.
189. O'Riordan CR, Song A. PEGylated adenovirus for targeted gene therapy. Methods Mol Biol. 2008;434:133-160.
190. Eto Y, Yoshioka Y, Mukai Y, Okada N, Nakagawa S. Development of PEGylated adenovirus vector with targeting ligand. Int J Pharm. 2008;354(1-2):3-8.
191. Eto Y, Gao JQ, Sekiguchi F, et al. Neutralizing antibody evasion ability of adenovirus vector induced by the bioconjugation of methoxypolyethylene glycol succinimidyl propionate (MPEG-SPA). Biol Pharm Bull. 2004;27(6):936-938.
192. Eto Y, Gao JQ, Sekiguchi F, et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med. 2005; 7(5):604-612.
193. Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther. 2005;11(1):66-79.
194. Croyle MA, Le HT, Linse KD, et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther. 2005;12(7):579-587.
195. Zabaleta A, Llopiz D, Arribillaga L, et al. Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein. Mol Ther. 2008;16(1):210-217.
196. Roth JC, Curiel DT, Pereboeva L. Cell vehicle targeting strategies. Gene Ther. 2008;15(10):716-729.
197. Bangari DS, Mittal SK. Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther. 2006;6(2):215-226.
198. Brown BD, Shi CX, Rawle FE, et al. Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice. J Thromb Haemost. 2004;2(1):111-118.
199. de Geest B, Snoeys J, van Linthout S, Lievens J, Collen D. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. Hum Gene Ther. 2005;16(12):1439-1451.
200. Morral N, O'Neal W, Rice K, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci U S A. 1999;96(22):12816-12821.
201. Hutnick NA, Carnathan DG, Dubey SA, et al. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirusspecific CD4+ T cells. Nat Med. 2009;15(8):876-878.
202. Kaufman DR, Barouch DH. Translational mini-review series on vaccines for HIV: T lymphocyte trafficking and vaccine-elicited mucosal immunity. Clin Exp Immunol. 2009;157(2):165-173.
203. Kaufman DR, Bivas-Benita M, Simmons NL, Miller D, Barouch DH. Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. J Virol. 2010;84(12):5986-5996.
204. Cheng C, Gall JG, Nason M, et al. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol. 2010;84(1):630-638.
205. Ogra PL, Karzon DT. Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine. J Immunol. 1969; 102(6):1423-1430.
206. Ogra PL, Ogra SS, al-Nakeeb S, Coppola PR. Local antibody response to experimental poliovirus infection in the central nervous system of rhesus monkeys. Infect Immun. 1973;8(6):931-937.
207. Ahlers JD, Belyakov IM. Strategies for optimizing targeting and delivery of mucosal HIV vaccines. Eur J Immunol. 2009;39(10):2657-2669.
208. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004; 200(6):761-770.
209. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200(6):749-759.
210. Belyakov IM, Hel Z, Kelsall B, et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med. 2001;7(12):1320-1326.
211. Belyakov IM, Kuznetsov VA, Kelsall B, et al. Impact of vaccineinduced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood. 2006;107(8):3258-3264.
212. Belyakov IM, Isakov D, Zhu Q, Dzutsev A, Berzofsky JA. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. J Immunol. 2007;178(11):7211-7221.
213. Staats HF, Montgomery SP, Palker TJ. Intranasal immunization is superior to vaginal, gastric, or rectal immuni - zation for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res Hum Retroviruses. 1997;13(11): 945-952.
214. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun. 1997;65(4):1387-1394.
215. Gorelick RJ, Benveniste RE, Gagliardi TD, et al. Nucleocapsid protein zinc-finger mutants of simian immunodeficiency virus strain mne produce virions that are replication defective in vitro and in vivo. Virology. 1999;253(2):259-270.
216. Sauter MM, Pelchen-Matthews A, Bron R, et al. An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface. J Cell Biol. 1996;132(5): 795-811.
217. Hessell AJ, Rakasz EG, Tehrani DM, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol. 2010;84(3):1302-1313.
218. Natuk RJ, Lubeck MD, Chanda PK, et al. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res Hum Retroviruses. 1993;9(5):395-404.
219. Lubeck MD, Natuk R, Myagkikh M, et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med. 1997;3(6):651-658.
220. Patterson LJ, Malkevitch N, Venzon D, et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol. 2004;78(5):2212-2221.
221. Malkevitch N, Rohne D, Pinczewski J, et al. Evaluation of combination DNA/replication-competent Ad-SIV recombinant immunization regimens in rhesus macaques. AIDS Res Hum Retroviruses. 2004;20(2):235-244.
222. Lemiale F, Haddada H, Nabel GJ, Brough DE, King CR, Gall JG. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine. 2007;25(11):2074-2084.
223. Christensen ML. Human viral gastroenteritis. Clin Microbiol Rev. 1989;2(1):51-89.
224. Favier AL, Burmeister WP, Chroboczek J. Unique physicochemical properties of human enteric Ad41 responsible for its survival and replication in the gastrointestinal tract. Virology. 2004;322(1): 93-104.
225. Pieniazek NJ, Slemenda SB, Pieniazek D, Velarde J Jr, Luftig RB. Human enteric adenovirus type 41 (Tak) contains a second fiber protein gene. Nucleic Acids Res. 1990;18(7):1901.
226. McConnell MJ, Hanna PC, Imperiale MJ. Adenovirus-based primeboost immunization for rapid vaccination against anthrax. Mol Ther. 2007;15(1):203-210.
227. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000;408(6812):605-609.
228. Liu RY, Wu LZ, Huang BJ, et al. Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats. Virus Res. 2005;112(1-2):24-31.
229. Gomez-Roman VR, Robert-Guroff M. Adenoviruses as vectors for HIV vaccines. AIDS Rev. 2003;5(3):178-185.
230. McConnell MJ, Danthinne X, Imperiale MJ. Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol. 2006;80(11):5361-5370.
231. Schief WR, Ban YE, Stamatatos L. Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS. 2009;4(5):431-440.
232. Lin G, Nara PL. Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein. Curr HIV Res. 2007;5(6):514-541.
233. Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol. 2010;22(3):358-366.
234. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature. 2008;455(7209):109-113.
235. Zhou T, Xu L, Dey B, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature. 2007;445(7129):732-737.
236. Lifson JD, Martin MA. One step forwards, one step back. Nature. 2002;415(6869):272-273.
237. Letvin NL, Barouch DH, Montefiori DC. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol. 2002;20:73-99.
238. Worgall S, Busch A, Rivara M, et al. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J Virol. 2004;78(5): 2572-2580.
239. Worgall S, Krause A, Rivara M, et al. Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest. 2005;115(5):1281-1289.
240. Matthews QL, Yang P, Wu Q, et al. Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. J Virol. 2008;5:98.
241. Krause A, Joh JH, Hackett NR, et al. Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J Virol. 2006;80(11):5523-5530.
242. Crompton J, Toogood CI, Wallis N, Hay RT. Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol. 1994; 75(Pt 1):133-139.
243. Wu H, Han T, Belousova N, et al. Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol. 2005;79(6): 3382-3390.
244. Rux JJ, Kuser PR, Burnett RM. Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution X-ray crystallographic, molecular modeling, and sequence-based methods. J Virol. 2003;77(17):9553-9566.
245. Worgall S, Krause A, Qiu J, Joh J, Hackett NR, Crystal RG. Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. J Virol. 2007;81(24):13801-13808.
246. Vigne E, Mahfouz I, Dedieu JF, Brie A, Perricaudet M, Yeh P. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol. 1999;73(6):5156-5161.
247. Abe S, Okuda K, Ura T, et al. Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. J Gene Med. 2009;11(7):570-579.
248. Ofek G, Tang M, Sambor A, et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol. 2004;78(19): 10724-10737.
249. Matthews QL, Sibley DA, Wu H, et al. Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion. Mol Imaging. 2006;5(4):510-519.
250. Tang Y, Le LP, Matthews QL, Han T, Wu H, Curiel DT. Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX. Virology. 2008;377(2):391-400.
251. Li J, Le L, Sibley DA, Mathis JM, Curiel DT. Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. Virology. 2005;338(2):247-258.
252. Matthews QL, Fatima A, Tang Y, et al. HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One. 2010;5(7):e11815.
253. Smith AD, Resnick DA, Zhang A, Geisler SC, Arnold E, Arnold GF. Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequences. J Virol. 1994;68(1): 575-579.
254. Brown T, Peerapatanapokin W. The Asian Epidemic Model: a process model for exploring HIV policy and programme alternatives in Asia. Sex Transm Infect. 2004;80 Suppl 1:i19-i24.
255. Phoolcharoen W. HIV/AIDS prevention in Thailand: success and challenges. Science. 1998;280(5371):1873-1874.
256. Weniger BG, Limpakarnjanarat K, Ungchusak K, et al. The epidemiology of HIV infection and AIDS in Thailand. AIDS. 1991;5 Suppl 2: S71-S85.
257. Nitayaphan S, Brown AE. Preventive HIV vaccine development in Thailand. AIDS. 1998;12 Suppl B:S155-S161.
258. Hanenberg RS, Rojanapithayakorn W, Kunasol P, Sokal DC. Impact of Thailand's HIV-control programme as indicated by the decline of sexually transmitted diseases. Lancet. 1994;344(8917):243-245.
259. Nelson KE, Celentano DD, Suprasert S, et al. Risk factors for HIV infection among young adult men in northern Thailand. JAMA. 1993;270(8):955-960.
260. Rerks-Ngarm S, Brown AE, Khamboonruang C, Thongcharoen P, Kunasol P. HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand. AIDS. 2006;20(11):1471-1479.